Cowen reaffirmed their buy rating on shares of Seres Therapeutics (NASDAQ:MCRB) in a report released on Tuesday morning, AnalystRatings.com reports.
Several other equities research analysts also recently commented on MCRB. HC Wainwright reiterated a buy rating and set a $8.00 target price on shares of Seres Therapeutics in a report on Friday, May 3rd. ValuEngine upgraded Seres Therapeutics from a sell rating to a hold rating in a report on Wednesday, March 27th. BidaskClub downgraded Seres Therapeutics from a hold rating to a sell rating in a report on Friday, May 3rd. Zacks Investment Research downgraded Seres Therapeutics from a buy rating to a hold rating in a report on Wednesday, January 16th. Finally, Chardan Capital reiterated a buy rating and set a $15.00 target price on shares of Seres Therapeutics in a report on Thursday, May 2nd. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of $11.13.
Seres Therapeutics stock opened at $4.60 on Tuesday. Seres Therapeutics has a 12 month low of $4.42 and a 12 month high of $9.75.
Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.12). The firm had revenue of $7.32 million during the quarter, compared to analysts’ expectations of $8.61 million. Seres Therapeutics had a negative return on equity of 1,583.95% and a negative net margin of 301.60%. As a group, analysts predict that Seres Therapeutics will post -1.9 EPS for the current year.
Several large investors have recently made changes to their positions in the stock. DekaBank Deutsche Girozentrale raised its holdings in shares of Seres Therapeutics by 21.5% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 19,800 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 3,500 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Seres Therapeutics by 98.9% during the 1st quarter. Wells Fargo & Company MN now owns 20,313 shares of the biotechnology company’s stock valued at $139,000 after buying an additional 10,102 shares during the period. Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in shares of Seres Therapeutics during the 1st quarter valued at about $5,504,000. JPMorgan Chase & Co. grew its stake in Seres Therapeutics by 51.9% during the 1st quarter. JPMorgan Chase & Co. now owns 605,849 shares of the biotechnology company’s stock valued at $4,163,000 after purchasing an additional 207,058 shares in the last quarter. Finally, Alpine Woods Capital Investors LLC acquired a new stake in Seres Therapeutics during the 1st quarter valued at approximately $412,000. Institutional investors and hedge funds own 79.26% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
Recommended Story: What is a blue-chip stock?
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.